Health biotech firms with developing country partners better postitioned to innovate, prosper

McLaughlin-Rotman Centre for Global Health

9 Sep 2009

Lower manufacturing, clinical trial, R&D costs of developing country partners equal major opportunities to advance global health, market position

Collaboration with health biotech companies in developing countries represents a major opportunity for companies in developed countries to strengthen their market reach and innovation potential, acording to the results of a new study.

The study by the McLaughlin-Rotman Centre for Global Health (MRC), based at the University Health Network and the University of Toronto, found that one in four Canadian health biotech firms are involved in some form of partnership initiative in developing countries.

Full news release text, click here

Example coverage, by LiveMint, India, click here